Alert FDA Approves Repotrectinib for ROS1-Positive NSCLC The next-generation tyrosine kinase inhibitor provides a new treatment option for patients with this difficult-to-treat form of lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback